🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Turkey / NCT07690137
Starting soon Observational

Pelvic Floor Symptoms Across Menopausel Stages

NCT07690137 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-07-06
Last updated
2026-07-09

Condition(s) studied

MenopausePerimenopausal Disorder

Investigational drug(s) / intervention(s)

Assessment for Lower Urinary Tract SymptomsAssessment for Bowel SymptomsConstipation Severity AssessmentSexual Function Assessment

Assessment for Lower Urinary Tract Symptoms: Lower urinary tract symptoms will be assessed using the validated Bristol Female Lower Urinary Tract Symptoms questionnaire. Higher scores indicate greater symptom severity and poorer urinary health-related quality of life.

Assessment for Bowel Symptoms: Bowel symptoms and colorectal-anal distress will be evaluated using the Colorectal Anal Distress Inventory-8. Higher scores indicate greater symptom severity and distress related to bowel dysfunction.

Constipation Severity Assessment: Constipation severity will be assessed using the Cleveland Clinic Constipation Score. Higher scores represent more severe constipation symptoms.

Sexual Function Assessment: Female sexual function will be assessed using the Female Sexual Function Index, a validated questionnaire evaluating desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate better sexual function.

Study summary

The menopausal transition is associated with substantial hormonal alterations that may adversely affect lower urinary tract function, bowel function, and sexual health. Although these symptoms are common, few studies have comprehensively evaluated all three pelvic floor compartments across different menopausal stages.

The aim of this study is to compare lower urinary tract symptoms, bowel symptoms, and female sexual function among women in the perimenopausal, early postmenopausal, and late postmenopausal stages. In addition, the relationship between menopausal stage and symptom severity will be investigated.

Eligibility

Sex
FEMALE
Min age
40 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Female * Age 40-65 years * Intact uterus and at least one ovary * Perimenopause or postmenopause according to STRAW+10 criteria * Able to read and understand Turkish Exclusion Criteria: * Hormone replacement therapy within the previous 6 months * Oral contraceptive use * Antipsychotic medication use * Previous pelvic surgery * Neurological or systemic diseases affecting bladder or bowel function * Active urinary tract or vaginal infection * Pelvic radiotherapy or chemotherapy history * Active gynecological or urological malignancy * Alcohol or substance abuse during the previous year

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Bezmialem Vakif University Istanbul Turkey (Türkiye)

More Bezmialem Vakif University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07690137 on ClinicalTrials.gov ↗ ← All trials in Turkey